Evaluation of the protective effect of a prime-boost strategy with plasmid DNA followed by recombinant adenovirus expressing BmAMA1 as vaccines against Babesia microti infection in hamster
暂无分享,去创建一个
X. Xuan | A. Efstratiou | Guanbo Wang | Mo Zhou | Mingming Liu | Jixu Li | Huanping Guo | Yang Gao | A. Ringo | S. Cao | Paul Frank Adjou Moumouni | Long-zheng Yu | Mingming Liu
[1] L. Aravind,et al. Expression, Purification, and Biological Characterization of Babesia microti Apical Membrane Antigen 1 , 2015, Infection and Immunity.
[2] A. Cowman,et al. Insights and controversies into the role of the key apicomplexan invasion ligand, Apical Membrane Antigen 1. , 2014, International journal for parasitology.
[3] D. Barto,et al. Babesiosis , 2014 .
[4] K. Fujisaki,et al. Protective effect of a prime-boost strategy with plasmid DNA followed by recombinant adenovirus expressing TgAMA1 as vaccines against Toxoplasma gondii infection in mice. , 2012, Parasitology international.
[5] Hiroshi Suzuki,et al. Construction of Neospora caninum stably expressing TgSAG1 and evaluation of its protective effects against Toxoplasma gondii infection in mice. , 2010, Vaccine.
[6] J. Barnwell,et al. High Antibody Titer against Apical Membrane Antigen-1 Is Required to Protect against Malaria in the Aotus Model , 2009, PloS one.
[7] H. Nakhasi,et al. CONFERENCE REPORT: Transfusion‐transmitted babesiosis in the United States: summary of a workshop , 2009, Transfusion.
[8] M. Young,et al. Persistent and relapsing babesiosis in immunocompromised patients. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] Richard J. Anderson,et al. Plasmid DNA and viral vector-based vaccines for the treatment of cancer. , 2007, Vaccine.
[10] M. Kiehntopf,et al. First confirmed autochthonous case of human Babesia microti infection in Europe , 2007, European Journal of Clinical Microbiology & Infectious Diseases.
[11] J. Harty,et al. Viral vector vaccines make memory T cells against malaria , 2007, Immunology.
[12] P. Morris,et al. Molecular characterisation of pneumococcal serotype 16F: Established predominant carriage and otitis media serotype in the 7vPCV era. , 2007, Vaccine.
[13] R. Gazzinelli,et al. Vaccination with replication-deficient recombinant adenoviruses encoding the main surface antigens of toxoplasma gondii induces immune response and protection against infection in mice. , 2006, Human gene therapy.
[14] M. Esteban,et al. MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis. , 2006, Microbes and infection.
[15] A. Marathe,et al. Human babesiosis--a case report. , 2005, Indian journal of medical microbiology.
[16] A. Campos-Neto. What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery? , 2005, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[17] David L Woodland,et al. Jump-starting the immune system: prime-boosting comes of age. , 2004, Trends in immunology.
[18] A. Hill,et al. Prime-boost strategies for malaria vaccine development , 2003, Journal of Experimental Biology.
[19] Y. Nagai,et al. Protective Efficacy of an AIDS Vaccine, a Single DNA Priming Followed by a Single Booster with a Recombinant Replication-Defective Sendai Virus Vector, in a Macaque AIDS Model , 2003, Journal of Virology.
[20] B. Keegan,et al. Vaccination of Monkeys with Recombinant Plasmodium falciparum Apical Membrane Antigen 1 Confers Protection against Blood-Stage Malaria , 2002, Infection and Immunity.
[21] A. Ramsay,et al. The prime-boost strategy: exciting prospects for improved vaccination. , 2000, Immunology today.
[22] A. Saito,et al. Roles of CD4+ T Cells and Gamma Interferon in Protective Immunity against Babesia microtiInfection in Mice , 1999, Infection and Immunity.
[23] R. Wilson,et al. The profile of IgG1 and IgG2a antibody responses in mice exposed to Schistosoma mansoni , 1994, Parasite immunology.
[24] C. V. von Essen. The Treatment of Cancer , 1966, Nature.
[25] Hiroshi Suzuki,et al. Expression of truncated Babesia microti apical membrane protein 1 and rhoptry neck protein 2 and evaluation of their protective efficacy. , 2017, Experimental parasitology.
[26] J. Ulmer,et al. Human clinical trials of plasmid DNA vaccines. , 2005, Advances in genetics.
[27] B. Wahrén. Gene vaccines. , 1996, Immunotechnology : an international journal of immunological engineering.
[28] F. Cox. Human babesiosis , 1980, Nature.